Clinical Trials Directory

Trials / Unknown

UnknownNCT04005781

Effect of Bitter in Overweight Female Volunteers

The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Overweight Female Subjects

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

We want to investigate whether an acute administration of hydroxychloroquine sulphate affects hedonic food intake, appetite related sensations and gastrointestinal hormone release in overweight female subjects.

Detailed description

Intragastric administration of a quinine-solution has shown to decrease hedonic food intake in healthy female volunteers. The effect of a tablet containing hydroxychloroquine sulphate on hedonic food intake in overweight female individuals has not been studied to date. The primary outcome of the current study is to evaluate the effect of hydroxychloroquine sulphate on hedonic food intake, assessed by ad libitum food intake of a chocolate milkshake one hour after dosing. The study is a randomized, placebo-controlled, double blinded cross-over study. Forty overweight females will be recruited. An acute dose of 400 mg hydroxychloroquine sulphate will be administered. Blood samples will be collected at regular time points to measure gastrointestinal hormone release and whole blood glucose levels. Appetite-related sensations will be scored at regular time points on visual analog scales.

Conditions

Interventions

TypeNameDescription
DRUGHydroxychloroquine sulphateAfter a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
DRUGPlaceboAfter a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.

Timeline

Start date
2019-10-01
Primary completion
2020-10-01
Completion
2020-10-01
First posted
2019-07-02
Last updated
2019-07-02

Source: ClinicalTrials.gov record NCT04005781. Inclusion in this directory is not an endorsement.